The estimated Net Worth of Stephen Mitchener is at least $615 Tausend dollars as of 28 February 2023. Mr. Mitchener owns over 6,357 units of Axcella Health Inc stock worth over $587,674 and over the last 5 years he sold AXLA stock worth over $27,505. In addition, he makes $0 as Senior Vice President und Chief Business Officer at Axcella Health Inc.
Sign up
Mr. Mitchener AXLA stock SEC Form 4 insiders trading
Stephen has made over 4 trades of the Axcella Health Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 6,357 units of AXLA stock worth $19,262 on 28 February 2023.
The largest trade he's ever made was selling 6,357 units of Axcella Health Inc stock on 28 February 2023 worth over $19,262. On average, Stephen trades about 1,269 units every 91 days since 2019. As of 28 February 2023 he still owns at least 128,313 units of Axcella Health Inc stock.
You can see the complete history of Mr. Mitchener stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stephen Mitchener biography
Stephen Mitchener Pharm.D. serves as Senior Vice President, Chief Business Officer of the Company. Prior to joining us, Dr. Mitchener served in increasing roles of responsibility at Novartis Pharmaceuticals Corporation from April 2005 to August 2018, most recently as Head of U.S. Oncology Strategy, Partnering and Operations. He previously served as a board observer for COTA Healthcare on behalf of Novartis Oncology.
How old is Stephen Mitchener?
Stephen Mitchener is 41, he's been the Senior Vice President und Chief Business Officer of Axcella Health Inc since . There are 16 older and 1 younger executives at Axcella Health Inc. The oldest executive at Axcella Health Inc is Catherine Sohn, 67, who is the Independent Director.
What's Stephen Mitchener's mailing address?
Stephen's mailing address filed with the SEC is C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON, MA, 02459.
Insiders trading at Axcella Health Inc
Over the last 6 years, insiders at Axcella Health Inc have traded over $32,393 worth of Axcella Health Inc stock and bought 29,966,648 units worth $79,278,835 . The most active insiders traders include Ventures Fund Iv General Pa..., Ventures Fund Iv General Pa... und Des Produits Nestle S.A.Nes.... On average, Axcella Health Inc executives and independent directors trade stock every 31 days with the average trade being worth of $3,073,698. The most recent stock trade was executed by Margaret Koziel on 1 March 2023, trading 679 units of AXLA stock currently worth $394.
What does Axcella Health Inc do?
axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.
What does Axcella Health Inc's logo look like?
Complete history of Mr. Mitchener stock trades at Karyopharm Therapeutics Inc und Axcella Health Inc
Axcella Health Inc executives and stock owners
Axcella Health Inc executives and other stock owners filed with the SEC include:
-
Shreeram Aradhye,
Executive Vice President, Chief Development Officer -
Manu Chakravarthy,
Senior Vice President, Chief Medical Officer -
William Hinshaw,
President, Chief Executive Officer, Director -
David Epstein,
Chairman of the Board -
William R. Hinshaw Jr.,
Pres, CEO & Director -
Laurent Chardonnet,
Consultant -
William Baird,
Independent Director -
Catherine Sohn,
Independent Director -
Gary Pisano,
Independent Director -
Gregory Behar,
Independent Director -
Cristina Rondinone,
Independent Director -
Stephen Hoge,
Independent Director -
Stephen Mitchener,
Senior Vice President, Chief Business Officer -
Paul Fehlner,
Senior Vice President, Chief Intellectual Property Officer -
Heidy King-Jones,
Senior Vice President of Legal, General Counsel -
Tony Tramontin,
Senior Vice President of Research and Development , Chief Scientific Officer -
Laurent Chardonnet,
Chief Financial Officer, Senior Vice President -
Karim Azer Ph.D.,
VP of Systems Biology & Discovery -
Dr. Margaret Koziel M.D.,
Sr. VP & Chief Medical Officer -
Dr. Alison D. Schecter M.D.,
Pres of R&D -
Dr. Larry Bell,
Global Head of Regulatory Affairs & Pharmacovigilance and Sr. VP -
Virginia R. Dean,
Sr. VP & Chief People Officer -
Dr. Paul Fehlner J.D., Ph.D.,
Sr. VP, Chief Legal Officer & Corp. Sec. -
Jason Fredette,
VP of Investor Relations & Corp. Communications -
Health Science Us Holdings,...,
-
Michael Rosenblatt,
Director -
David A Berry,
Director -
Ventures Fund Iv General Pa...,
-
Paul J Sekhri,
Director -
Ventures Fund Iv General Pa...,
-
Des Produits Nestle S.A.Nes...,
-
Alison D. Schecter,
President - Research & Dev. -
Virginia R Dean,
SVP, Chief People Officer -
Margaret Koziel,
Chief Medical Officer -
Ventures Fund Iv General Pa...,
-
Robert Crane,
Chief Financial Officer -
Torben Straight Nissen,
Director -
Robert L. Rosiello,
Director